HexemBio
Pioneering the first-ever blood rejuvenation therapy.
Healthcare & Biotech
Vision
HeXem Bio is pioneering the first-ever blood rejuvenation therapy. Our revolutionary technology, validated by leading global institutions and featured in prestigious publications such as Nature and The New York Times, offers a transformative approach to extending human healthspan. HeXem Bio’s proprietary technology rejuvenates cells to a youthful state, enhancing their capacity to regenerate the entire blood system. This breakthrough has profound implications not only for aging but also for patients suffering from various diseases, revolutionizing treatment options and improving quality of life on a global scale.
Sub-Industries
Regenerative Medicine
Anti-Aging Therapies
Blood Disorder Treatments
Testimonial
Draper Associates Leads HexemBio's $10.4M Seed to Rejuvenate Aging Blood Stem Cells
We led HexemBio's $10.4M seed to rejuvenate aging blood stem cells, starting with patients fighting blood cancer.
Read →
Your blood stem cells are the source of your entire immune system. As they age, your body's defenses weaken. We led HexemBio's $10.4 million seed round because the company found a way to make old blood stem cells young again, without gene editing.
Rejuvenation outside the body
HexemBio uses a proprietary synthetic niche, an engineered environment that mimics the conditions where stem cells are born, to rejuvenate a patient's own blood stem cells outside the body. The renewed cells are then returned through a standard IV infusion. The first clinical target is blood cancer, where rebuilding a healthy immune system can be the difference between recovery and relapse.
The company emerged from stealth with our round. It was founded by CEO Gabriel Levesque Tremblay alongside CTO Samira Kiani and CBO Samet Yildirim. We led the seed, joined by SOSV, Seraphim Space, and Treeo VC.
Why we led the round
We fund the future first, and few futures are bigger than changing how we age, extending healthy human lifespan. The premise is simple: the decline of blood stem cells is a major driver of aging itself. Start with the bone marrow transplant patients who need it most, prove the science in the clinic, and the long-term implications reach far beyond any single disease. That is precisely the kind of audacious, well-grounded bet we look for, and we are proud to lead it.
Related Companies
KindBio
The future of organ replacement
Salem, NH, USA
The Embryo Corporation
Scalable embryo gene editing to build the next generation of animal life
Austin, TX, USA
Paterna Biosciecnes
In vitro gematogenesis platform company to address male and female intertility
Salt Lake City, UT, USA
Proton Intelligence
Real-time wearable potassium monitoring
Vancouver, Canada
Origenity
AI-driven cell design, from next-generation genetic medicines to expanding what life can be
San Francisco, USA
Deep Root Biolabs
Plant-powered synthetic biology turning polluted soil into clean ground and reclaimed critical minerals
Baltimore, MD, USA
LightHearted AI
Revolutionizing Point-of-Care Cardiac Detection Using Photonics and AI
London, UK
